153 related articles for article (PubMed ID: 17699862)
1. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Takimoto CH; Graham MA; Lockwood G; Ng CM; Goetz A; Greenslade D; Remick SC; Sharma S; Mani S; Ramanathan RK; Synold TW; Doroshow JH; Hamilton A; Mulkerin DL; Ivy P; Egorin MJ; Grem JL
Clin Cancer Res; 2007 Aug; 13(16):4832-9. PubMed ID: 17699862
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow J; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Schuler B; Greenslade D; Goetz A; Knight R; Thomas R; Monahan BP; Dahut W; Grem JL;
J Clin Oncol; 2003 Jul; 21(14):2664-72. PubMed ID: 12860942
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
5. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow JH; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Greenslade D; Goetz A; Grem JL
Semin Oncol; 2003 Aug; 30(4 Suppl 15):20-5. PubMed ID: 14523791
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of topotecan in patients with impaired renal function.
O'Reilly S; Rowinsky EK; Slichenmyer W; Donehower RC; Forastiere AA; Ettinger DS; Chen TL; Sartorius S; Grochow LB
J Clin Oncol; 1996 Dec; 14(12):3062-73. PubMed ID: 8955651
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
Synold TW; Takimoto CH; Doroshow JH; Gandara D; Mani S; Remick SC; Mulkerin DL; Hamilton A; Sharma S; Ramanathan RK; Lenz HJ; Graham M; Longmate J; Kaufman BM; Ivy P;
Clin Cancer Res; 2007 Jun; 13(12):3660-6. PubMed ID: 17575231
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.
Gietema JA; de Vries EG; Sleijfer DT; Willemse PH; Guchelaar HJ; Uges DR; Aulenbacher P; Voegeli R; Mulder NH
Br J Cancer; 1993 Feb; 67(2):396-401. PubMed ID: 8431374
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
Gretler DD; Guerciolini R; Williams PJ
Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
[TBL] [Abstract][Full Text] [Related]
13. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
[TBL] [Abstract][Full Text] [Related]
17. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
19. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
Azaro A; Rodón J; Machiels JP; Rottey S; Damian S; Baird R; Garcia-Corbacho J; Mathijssen RHJ; Clot PF; Wack C; Shen L; de Jonge MJA
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1185-1197. PubMed ID: 27796539
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]